Guotai Junan Securities: Maintains Buy rating on BeiGene (06160.HK), Zanubrutinib becomes a global leader in the BTKi market.

Zhitong Finance APP learned that Guojin Securities issued a research report stating that considering BeiGene (06160.HK) as the leader in the domestic biopharmaceutical industry, its global layout has been remarkably effective, and both commercialization and research and development have reached critical turning points, maintaining a "buy" rating. The company's core products are experiencing a rapid increase in sales volume, its international layout is accelerating, and the research and development pipeline is expected to see intensive catalysis. The company's profitability in the third quarter of 2025 continues to show a trend of sustained improvement, with the net profit forecast for 2025-2027 being raised to 3.12/7.95/12.22 billion US dollars.